Beyond Sativex: GW Launches Cannabinoid Cancer Clinical Program
LONDON – GW Pharmaceuticals plc has advanced its expertise in cannabis pharmacology to the next stage, starting the first formal clinical trial of a cannabinoid as an antitumor therapeutic. “There is a lot of preclinical evidence in the literature, but in terms of clinical development, this is the first time a natural cannabinoid has been tested in cancer,” said Justin Gover, CEO.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST